Methods for optimizing antiviral combination therapies

Bioinformatics

Volumn 19, Issue SUPPL. 1, 2003, Pages

  Beerenwinkel, Niko ^a   Lengauer, Thomas ^a   Däumer, Martin ^b   Kaiser, Rolf ^b   Walter, Hauke ^c   Korn, Klaus ^c   Hoffmann, Daniel ^d   Selbig, Joachim ^e  

^a MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d CENTER OF ADVANCED EUROPEAN STUDIES AND RESEARCH CAESAR   (Germany)

^e MAX PLANCK INSTITUTE OF MOLECULAR PLANT PHYSIOLOGY   (Germany)

Author keywords

Antiretroviral therapy; Drug resistance; HIV; Sequence space search; SVM regression; Therapy optimization

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS DNA;

BIOINFORMATICS; COMPUTER MODEL; CONFERENCE PAPER; DNA SEQUENCE; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROBABILITY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; ALGORITHM; ANTIBIOTIC RESISTANCE; ARTICLE; ARTIFICIAL INTELLIGENCE; AUTOMATED PATTERN RECOGNITION; BIOLOGICAL MODEL; CLASSIFICATION; CLINICAL TRIAL; CLUSTER ANALYSIS; COMPARATIVE STUDY; COMPUTER ANALYSIS; COMPUTER ASSISTED DRUG THERAPY; DRUG COMBINATION; DRUG EFFECT; GENE EXPRESSION PROFILING; GENETIC POLYMORPHISM; GENETICS; HUMAN; METHODOLOGY; PHENOTYPE; QUALITY CONTROL; REGRESSION ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; VALIDATION STUDY; VIROLOGY; VIRUS GENOME;

ALGORITHMS; ANTI-HIV AGENTS; ARTIFICIAL INTELLIGENCE; CLUSTER ANALYSIS; COMPUTING METHODOLOGIES; DNA, VIRAL; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMPUTER-ASSISTED; GENE EXPRESSION PROFILING; GENOME, VIRAL; HIV; HIV INFECTIONS; HUMANS; MODELS, GENETIC; MODELS, STATISTICAL; PATTERN RECOGNITION, AUTOMATED; PHENOTYPE; POLYMORPHISM, GENETIC; QUALITY CONTROL; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 0344808232     PISSN: 13674803     EISSN: 13674811     Source Type: Journal    
DOI: 10.1093/bioinformatics/btg1001     Document Type: Conference Paper

References (24)

1. Beerenwinkel, N., Schmidt, B., Walter, H., Kaiser, R., Lengauer, T., Hoffmann, D., Korn, K. and Selbig, J. (2001) Geno2pheno: interpreting genotypic HIV drug resistance tests. IEEE Intelligent Systems, 16, 35-41.
2. Beerenwinkel, N., Schmidt, B., Walter, H., Kaiser, R., Lengauer, T., Hoffmann, D., Korn, K. and Selbig, J. (2002a) Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc. Natl Acad. Sci. USA, 99, 8271-8276.
3. Beerenwinkel, N., Schmidt, B., Walter, H., Kaiser, R., Lengauer, T., Hoffmann, D., Korn, K. and Selbig, J. (2002b) Quantitative phenotype prediction by support vector machines. Antivir. Then., 7, S74.
4. Beerenwinkel, N., Däumer, M., Sierra-Aragon, S., Schmidt, B., Walter, H., Kom, K., Oette, M., Fätkenheuer, G., Rockstroh, J., Lengauer, T. et al. (2002) Geno2pheno is predictive of short-term virological response. Antivir. Ttier., 7, S74.
5. Burges, C.J.C. (1998) A tutorial on support vector machines for pattern recognition. Data Mining and Knowledge Discovery, 2, 121-167.
6. DeGruttola, V., Dix, L., D'Aquila, R., Holder, D., Phillips, A., Ait-Khaled, M., Baxter, J., Clevenbergh, P., Hammer, S. and Harrigan, R., et al. (2000) The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther., 5, 41-18.
7. De Luca, A., Vendittoli, M., Baldini, R., Di Giambenedetto, S., Rizzo, M.G., Trotta, M.R., Cingolani, A., Forbici, R., Perno, C.F., Antinori, A. and Ulivi, G. (2002) Construction, training and clinical validation of an inferential interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules learning from virological outcomes. Antivir. Ther., 7, S76.
8. Dempster, A., Laird, N. and Rubin, D. (1977) Maximum likelihood from incomplete data via the EM algorithm (with discussions). J. R. Statist. Soc. B, 39, 1-38.
9. Hastie, T., Tibshirani, T. and Friedman, J. (2001) The Elements of Statistical Learning. Springer, New York.
10. Holland, J.J., De La Torre, J.C. and Steinhauer, D.A. (1992) RNA virus populations as quasispecies. Curr. Top. Microbiol. Immunol., 176, 1-20.
11. Jetzt, A.E., Yu, H., Klarmann, G.J., Ron, Y., Preston, B.D. and Dougherty, J.P. (2000) High rate of recombination throughout the human immunodeficiency virus type 1 genome. J. Virol., 74, 1234-1240.
12. Jordan, R., Gold, L., Cummins, C. and Hyde, C. (2002) Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. British Med. J., 324, 1-10.
13. Jung, A., Maier, R., Vartanian, J.P., Bocharov, G., Jung, V., Fischer, U., Meese, E., Wain-Hobson, S. and Meyerhans, A. (2002) Multiply infected spleen cells in HIV patients. Nature, 418, 144.
14. Lathrop, R.H. and Pazzani, M.J. (1999a) Combinatorial optimization in rapidly mutating drug-resistant viruses. J. Comb. Optim., 3, 301-320.
15. Lathrop, R.H., Steffen, N.R., Raphael, M., Deeds-Rubin.S., Pazzani, M.J., Cimoch, P.J., See, D.M. and Tilles, J.G. (1999b) Knowledge-based avoidance of drug-resistant HIV mutants. AI Magazine, 20, 13-25.
16. Perrin, L. and Telenti, A. (1998) HIV treatment failure: testing for HIV resistance in clinical practice. Science, 280, 1871-1873.
17. Schmidt, B., Walter, H., Schwingel, E., Beerenwinkel, N., Selbig, J., Kaiser, R., Hoffmann, D., Shafer, R., Keulen, W., Been-Tiktak, A.M., Boucher, C.A. and Korn, K. (2001) Comparison of different interpretation systems for genotypic HIV-1 drug resistance data. Antivir. Ther., 6, 102.
18. Sevin, A.D., DeGruttola, V., Nijhuis, M., Schapiro, J.M., Foulkes, A.S., Para, M.F. and Boucher, C.A. (2000) Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333. J. Infect. Dis., 182, 59-67.
19. Shafer, R.W., Kantor, R. and Gonzales, M.J. (2000) The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Reviews, 2, 211-228.
20. Vandamme, A-M., Van Laethem, K. and De Clerq, E. (1999) Managing resistance to anti HIV drugs: an important consideration for effective disease management. Drugs, 57, 337-361.
21. Walter, H., Schmidt, B., Korn, K., Vandamme, A.M., Harrer, T. and Uberla, K. (1999) Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J. Clin. Virol., 13, 71-80.
22. Wang, D., Bloor, S. and Larder, B.A. (2000) The application of neural networks in predictingphenotypic resistance from genotypes for HIV-1 protease inhibitors. Antivir. Then, 5, 51-52.
23. Wildenberg, A., Skiena, S. and Sumazin, P. (2002) Deconvolving sequence variation in mixed DNA populations. Proceedings of the Sixth Annual International Conference on Computational Biology, pp. 311-320.
24. Zollner, B., Feucht, H.H., Schroter, M., Schäfer, P., Plettenberg, A., Stoehr, A. and Laufs, R. (2001) Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients. AIDS, 15, 935-936.